ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

STX Shield Therapeutics Plc

1.85
0.00 (0.00%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.85 1.80 1.90 1.85 1.85 1.85 572,013 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.35 14.35M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 1.85p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 12.75p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £14.35 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.35.

Shield Therapeutics Share Discussion Threads

Showing 21976 to 21992 of 23400 messages
Chat Pages: Latest  888  887  886  885  884  883  882  881  880  879  878  877  Older
DateSubjectAuthorDiscuss
28/9/2023
09:03
Yes but they get the tenners from PI's, so they are happy to do so.
encarter
28/9/2023
08:59
Here's another way to look at it... why would you hold it now? Given the track record, I'd much rather buy it at 20p in 2026 when they are making NET profits and miss out on this cycle of raise and repeat. They are paying tenners to make fivers at the moment. The maths doesn't work for me anymore, I'm out (at a ridiculous loss)
reviewwworld
28/9/2023
08:57
Sales are up, price per unit disappointing, more shares issued - jam tomorrow, but it keeps getting watered down in stock issues.
weatherman
28/9/2023
08:55
Question is whether to buy in the retail offer at 8p or whether to wait and see if the market takes the share price sub 8p.
husbod
28/9/2023
08:53
About 700 million shares in issue plus millions of warrants No way in million years this company should be worth 60 plus millionI see the share price tanking well below all time lowGet out whilst you can
hamidahamida
28/9/2023
08:51
How many did you buy this week patt ?
arab3
28/9/2023
08:46
When this placing will be done?
qipincha
28/9/2023
08:45
Stepping back from the hysteria, it is rather impressive to see this level of growth and the likelihood is that they will be hitting the upper end of the 100,000 to 130,000 prescriptions target for the year. With the Canada decision soon, the Korean PK study and the possibilities in China, too, there is a lot to be excited about for the company and the shareholders. US selling price trajectory is following a predictable path if you are experienced in market access (I work in a pharma market access function). AOP are no fools.
photon
28/9/2023
08:37
Funds for US listing?
little minx
28/9/2023
08:35
Imo No chance they are going to meet forecasts This is going well below the issue price Boiler room boys hv been stung
hamidahamida
28/9/2023
08:31
Why would you raise money after telling the market only few weeks ago they have enough money to reach break even. Pretty obvious it's probably becoming evident they are not going to meet forecasts hence the reason for this deeply discounted confetti party.
hamidahamida
28/9/2023
08:31
Early indications suggest Accrufer's(R) growth trajectory will continue to rise in Q3 2023, exceeding 28,400 prescriptions, representing an 80% sequential increase vs Q2. The prescriptions in Q3 2023 are on track to exceed the total for the entire first six months of the year. Excellent initial results following the commercial expansion put Shield on track to reach a major corporate milestone for 2023, with line of sight to total Accrufer(R) prescriptions of 100,000 to 130,000. Since the completion of the sales force expansion in May, Accrufer(R) has grown an average of 26% month over month through to the end of August.
qipincha
28/9/2023
08:27
You were saying?
little minx
28/9/2023
08:24
Look on the Brightside folks

The placing is at a 0% discount to the share price today. What great business from the board.

lako42
28/9/2023
08:21
If you cannot see why LTH's are miffed with this latest raise, especially after the trading activity yesterday...then I simply do not believe you.
Sure, people could and some did, make money trading between the last raise and this one. And that is probably the only way to make money in this type of outfit. But it is essentially playing greater fool theory, because this is not the first time that irregular share price activity has taken place, followed by the predictable. Smaller and smaller potential returns for shareholders, while the BOD feast.
Actual update OK, but even if they do eventually stop relying on placings to keep as a going concern, no doubt the BOD will elevate their remuneration even higher than it already is. Meaning actual long term investors, even if they had participated in all the raises, are going to make only a small profit, at best. No way is this going to be a 10 bagger, because they are going to keep rewarding themselves ever greater chunks of the company.
Anyway, it is what it is on AIM. GLA.

lovewinshatelosses
28/9/2023
08:20
Says it all.
little minx
28/9/2023
08:17
Ok, back to August time, and hold
qipincha
Chat Pages: Latest  888  887  886  885  884  883  882  881  880  879  878  877  Older